title: Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
authors.forename: Bipin N
authors.initials: BN
authors.lastname: Savani
authors.forename: Paula R
authors.initials: PR
authors.lastname: Pohlmann
authors.forename: Madan
authors.initials: M
authors.lastname: Jagasia
authors.forename: Wichai
authors.initials: W
authors.lastname: Chinratanalab
authors.forename: Adetola
authors.initials: A
authors.lastname: Kassim
authors.forename: Brian
authors.initials: B
authors.lastname: Engelhardt
authors.forename: John
authors.initials: J
authors.lastname: Greer
authors.forename: Friedrich
authors.initials: F
authors.lastname: Schuening
authors.forename: Stacey
authors.initials: S
authors.lastname: Goodman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000628:therapy / Q000821:virology*; D018380:Hematopoietic Stem Cell Transplantation; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000628:therapy / Q000821:virology*; D000069283:Rituximab; D014184:Transplantation, Homologous; D014775:Virus Activation
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab